Baxter/Halozyme Hyaluronidase Enhanze SC Could See Approval By September

The firms are touting the hyaluronidase agent’s recombinant human origin as a key advantage over currently available animal-derived hyaluronidase products. Enhanze SC would be the third hyaluronidase on the market but the first that is human-derived.